Heather L Machado

Dr. Heather L Machado

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Bruno Sainz Jr.Bruno Sainz Jr.
Bruno Sainz Jr.
ECEmily Carron
Emily Carron
MVMireia Vallespinós
Mireia Vallespinós
HMHeather L Machado
Heather L Machado
Cancer stem cells (CSCs) are a unique subset of cells within tumors with stemlike properties that have been proposed to be key drivers of tumor initiation and progression. CSCs are functionally defined by their unlimited self-renewal capacity and their ability to initiate tumor formationin vivo. Like normal stem cells, CSCs exist in a cellular niche comprised of numerous cell types including tumor-associated macrophages (TAMs) which provides a unique microenvironment to protect and promote CSC functions. TAMs provide pivotal signals to promote CSC survival, self-renewal, maintenance, and migratory ability, and in turn, CSCs deliver tumor-promoting cues to TAMs that further enhance tumorigenesis. Studies in the last decade have aimed to understand the molecular mediators of CSCs and TAMs, and recent advances have begun to elucidate the complex cross talk that occurs between these two cell types. In this review, we discuss the molecular interactions that define CSC-TAM cross talk at each stage of tumor progression and examine the clinical implications of targeting these interactions.

31 January 2017 in Oncotarget
Verified
Journal Article
Open access
ECEmily C. Carron
Emily C. Carron
SHSamuel Homra
Samuel Homra
JRJillian Rosenberg
Jillian Rosenberg
SCSeth B. Coffelt
Seth B. Coffelt
FKFrances Kittrell
Frances Kittrell
HMHeather L Machado
Heather L Machado
Macrophages promote the progression of premalignant mammary lesions to invasive cancer

3 January 2017 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
GDGabriele D’errico
Gabriele D’errico
HMHeather L Machado
Heather L Machado
Bruno Sainz Jr.Bruno Sainz Jr.
Bruno Sainz Jr.
Immunotherapy is the new trend in cancer treatment due to the selectivity, long lasting effects, and demonstrated improved overall survival and tolerance, when compared to patients treated with conventional chemotherapy. Despite these positive results, immunotherapy is still far from becoming the perfect magic bullet to fight cancer, largely due to the facts that immunotherapy is not effective in all patients nor in all cancer types. How and when will immunotherapy overcome these hurdles? In this review we take a step back to walk side by side with the pioneers of immunotherapy in order to understand what steps need to be taken today to make immunotherapy effective across all cancers. While early scientists, such as Coley, elicited an unselective but effective response against cancer, the search for selectivity pushed immunotherapy to the side in favor of drugs focused on targeting cancer cells. Fortunately, the modern era would revive the importance of the immune system in battling cancer by releasing the brakes or checkpoints (anti‐CTLA‐4 and anti‐PD‐1/PD‐L1) that have been holding the immune system at bay. However, there are still many hurdles to overcome before immunotherapy becomes a universal cancer therapy. For example, we discuss how the redundant and complex nature of the immune system can impede tumor elimination by teeter tottering between different polarization states: one eliciting anti‐cancer effects while the other promoting cancer growth and invasion. In addition, we highlight the incapacity of the immune system to choose between a fight or repair action with respect to tumor growth. Finally we combine these concepts to present a new way to think about the immune system and immune tolerance, by introducing two new metaphors, the “push the accelerator” and “repair the car” metaphors, to explain the current limitations associated with cancer immunotherapy.

18 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ENEmma Newton
Emma Newton
LMLauren Mueller
Lauren Mueller
Scout M TreadwellScout M Treadwell
Scout M Treadwell
CMCindy A. Morris
Cindy A. Morris
HMHeather L Machado
Heather L Machado
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Due to its heterogeneity and lack of hormone receptor expression, this subtype is more likely to metastasize and resist treatment attempts than are other forms of breast cancer. Due to the absence of targetable receptors, chemotherapy and breast conserving surgery have been the predominant treatment options for patients. However, resistance to chemotherapy and local recurrence of the tumors is frequent. Emerging immunotherapies have begun to change treatment plans for patients diagnosed with TNBC. In this review, we discuss the various immune pathways identified in TNBC and the role they play as targets for new potential treatment choices. Various therapeutic options that inhibit key pathways in cellular growth cycles, DNA repair mechanisms, epithelial mesenchymal transition, and immunosuppression have been shown to improve survival in patients with this disease. With promising results thus far, continued studies of immunotherapy and neoadjuvant therapy options for TNBC are likely to alter the treatment course for these diagnoses in the future.

7 December 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
AGAngelica M. Gomes
Angelica M. Gomes
ECEmily C. Carron
Emily C. Carron
KMKylie L. Mills
Kylie L. Mills
ADAlexa M. Dow
Alexa M. Dow
ZGZane Gray
Zane Gray
HMHeather L Machado
Heather L Machado

25 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
MMMegan G. Matherne
Megan G. Matherne
EPEmily S. Phillips
Emily S. Phillips
SESamuel J. Embrey
Samuel J. Embrey
CBCaitlin M. Burke
Caitlin M. Burke
HMHeather L Machado
Heather L Machado
Breast tumorigenesis relies on complex interactions between tumor cells and their surrounding microenvironment, orchestrated by tightly regulated transcriptional networks. C/EBPβ is a key transcription factor that regulates the proliferation and differentiation of multiple cell types and modulates a variety of biological processes such as tissue homeostasis and the immune response. In addition, C/EBPβ has well-established roles in mammary gland development, is overexpressed in breast cancer, and has tumor-promoting functions. In this review, we discuss context-specific roles of C/EBPβ during breast tumorigenesis, isoform-specific gene regulation, and regulation of the tumor immune response. We present challenges in C/EBPβ biology and discuss the importance of C/EBPβ isoform-specific gene regulation in devising new therapeutic strategies.